MATE™: Biohaven’s Novel, Peptide-Based Reagents Enable the Synthesis of Homogeneous and Well-Defined Antibody Conjugates

Antibody drug conjugates (ADCs) are a valuable therapeutic modality delivering significant improvements in survival outcomes for both solid tumor and hematological malignancies. Most of the approved ADCs are synthesized by non-specific, stochastic conjugations and result in complex mixtures, premature release of free payload, and high manufacturing costs. To address these challenges Biohaven developed a next generation, novel, site-specific, irreversible conjugation platform. Our MATE™ conjugation reagents take advantage of specific peptide-antibody interactions and enable single-step formation of highly homogeneous antibody conjugates, allowing the use of native antibodies and sidestepping the need for conjugation-facilitating antibody engineering. We will detail the design, synthesis of reagents, stability, and conjugation selectivity data across programs.